Table 1.
Open in new tab

Criteria proposed for clinical diagnosis of elevated triglyceride levels under fasting conditions

NCEP ATP III (3)The Endocrine Society 2010a
Normal<150 mg/dl<1.7 mmol/literNormal<150 mg/dl<1.7 mmol/liter
Borderline-high triglycerides150–199 mg/dl1.7–2.3 mmol/literMild hypertriglyceridemia150–199 mg/dl1.7–2.3 mmol/liter
High triglycerides200–499 mg/dl2.3–5.6 mmol/literModerate hypertriglyceridemia200–999 mg/dl2.3–11.2 mmol/liter
Very high triglycerides≥500 mg/dl≥5.6 mmol/literSevere hypertriglyceridemia1000–1999 mg/dl11.2–22.4 mmol/liter
Very severe hypertriglyceridemia≥2000 mg/dl≥22.4 mmol/liter
NCEP ATP III (3)The Endocrine Society 2010a
Normal<150 mg/dl<1.7 mmol/literNormal<150 mg/dl<1.7 mmol/liter
Borderline-high triglycerides150–199 mg/dl1.7–2.3 mmol/literMild hypertriglyceridemia150–199 mg/dl1.7–2.3 mmol/liter
High triglycerides200–499 mg/dl2.3–5.6 mmol/literModerate hypertriglyceridemia200–999 mg/dl2.3–11.2 mmol/liter
Very high triglycerides≥500 mg/dl≥5.6 mmol/literSevere hypertriglyceridemia1000–1999 mg/dl11.2–22.4 mmol/liter
Very severe hypertriglyceridemia≥2000 mg/dl≥22.4 mmol/liter
a

The criteria developed for the present guidelines focus on the ability to assess risk for premature CVD vs. risk for pancreatitis. The designations of mild and moderate hypertriglyceridemia correspond to the range of levels predominant in risk assessment for premature CVD, and this range includes the vast majority of subjects with hypertriglyceridemia. Severe hypertriglyceridemia carries a susceptibility for intermittent increases in levels above 2000 mg/dl and subsequent risk of pancreatitis; very severe hypertriglyceridemia is indicative of risk for pancreatitis. In addition, these levels suggest different etiologies. Presence of mild or moderate hypertriglyceridemia is commonly due to a dominant underlying cause in each patient, whereas severe or very severe hypertriglyceridemia is more likely due to several contributing factors.

Table 1.
Open in new tab

Criteria proposed for clinical diagnosis of elevated triglyceride levels under fasting conditions

NCEP ATP III (3)The Endocrine Society 2010a
Normal<150 mg/dl<1.7 mmol/literNormal<150 mg/dl<1.7 mmol/liter
Borderline-high triglycerides150–199 mg/dl1.7–2.3 mmol/literMild hypertriglyceridemia150–199 mg/dl1.7–2.3 mmol/liter
High triglycerides200–499 mg/dl2.3–5.6 mmol/literModerate hypertriglyceridemia200–999 mg/dl2.3–11.2 mmol/liter
Very high triglycerides≥500 mg/dl≥5.6 mmol/literSevere hypertriglyceridemia1000–1999 mg/dl11.2–22.4 mmol/liter
Very severe hypertriglyceridemia≥2000 mg/dl≥22.4 mmol/liter
NCEP ATP III (3)The Endocrine Society 2010a
Normal<150 mg/dl<1.7 mmol/literNormal<150 mg/dl<1.7 mmol/liter
Borderline-high triglycerides150–199 mg/dl1.7–2.3 mmol/literMild hypertriglyceridemia150–199 mg/dl1.7–2.3 mmol/liter
High triglycerides200–499 mg/dl2.3–5.6 mmol/literModerate hypertriglyceridemia200–999 mg/dl2.3–11.2 mmol/liter
Very high triglycerides≥500 mg/dl≥5.6 mmol/literSevere hypertriglyceridemia1000–1999 mg/dl11.2–22.4 mmol/liter
Very severe hypertriglyceridemia≥2000 mg/dl≥22.4 mmol/liter
a

The criteria developed for the present guidelines focus on the ability to assess risk for premature CVD vs. risk for pancreatitis. The designations of mild and moderate hypertriglyceridemia correspond to the range of levels predominant in risk assessment for premature CVD, and this range includes the vast majority of subjects with hypertriglyceridemia. Severe hypertriglyceridemia carries a susceptibility for intermittent increases in levels above 2000 mg/dl and subsequent risk of pancreatitis; very severe hypertriglyceridemia is indicative of risk for pancreatitis. In addition, these levels suggest different etiologies. Presence of mild or moderate hypertriglyceridemia is commonly due to a dominant underlying cause in each patient, whereas severe or very severe hypertriglyceridemia is more likely due to several contributing factors.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close